http://feeds.feedburner.com/runconferencehighlights Latest articles from Renal and Urology News Conference Highlights Conference Highlights Conference Highlights custserv@haymarketmedia.com no Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ. https://www.renalandurologynews.com/bladder-cancer-pembrolizumab-shows-promise-bcg/article/834774/ Tue, 19 Feb 2019 12:30:00 GMT Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ. https://www.renalandurologynews.com/bladder-cancer-pembrolizumab-shows-promise-bcg/article/834774/ Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy. https://www.renalandurologynews.com/bladder-cancer-mibc-radical-cystectomy-superior-trimodal-therapy/article/834775/ Tue, 19 Feb 2019 12:15:00 GMT Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy. https://www.renalandurologynews.com/bladder-cancer-mibc-radical-cystectomy-superior-trimodal-therapy/article/834775/ In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit. https://www.renalandurologynews.com/urothelial-cancer-radiation-chemotherapy-not-beneficial-treatment/article/834776/ Mon, 18 Feb 2019 19:00:00 GMT In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit. https://www.renalandurologynews.com/urothelial-cancer-radiation-chemotherapy-not-beneficial-treatment/article/834776/ Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-tivozanib-offers-superior-outcomes/article/834793/ Mon, 18 Feb 2019 19:00:00 GMT Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-tivozanib-offers-superior-outcomes/article/834793/ About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab. https://www.renalandurologynews.com/renal-cell-carcinoma-pembrolizumab-shows-promise-treatment/article/834790/ Mon, 18 Feb 2019 18:00:00 GMT About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab. https://www.renalandurologynews.com/renal-cell-carcinoma-pembrolizumab-shows-promise-treatment/article/834790/ Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-combination-superior-sunitinib/article/834789/ Mon, 18 Feb 2019 17:30:00 GMT Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-combination-superior-sunitinib/article/834789/ New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus. https://www.renalandurologynews.com/renal-cell-carcinoma-cabozantinib-early-tumor-shrinkage-better-survival/article/834788/ Mon, 18 Feb 2019 17:00:00 GMT New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus. https://www.renalandurologynews.com/renal-cell-carcinoma-cabozantinib-early-tumor-shrinkage-better-survival/article/834788/ Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-nivolumab-ipilimumab-survival-benefit/article/834787/ Mon, 18 Feb 2019 16:30:00 GMT Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-nivolumab-ipilimumab-survival-benefit/article/834787/ As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-two-drug-combo-superior-sunitinib/article/834786/ Mon, 18 Feb 2019 16:00:00 GMT As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib. https://www.renalandurologynews.com/renal-cell-carcinoma-rcc-two-drug-combo-superior-sunitinib/article/834786/ Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found. https://www.renalandurologynews.com/obese-men-with-metastatic-castration-resistant-prostate-cancer-live-longer/article/834758/ Sat, 16 Feb 2019 17:48:15 GMT Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found. https://www.renalandurologynews.com/obese-men-with-metastatic-castration-resistant-prostate-cancer-live-longer/article/834758/ Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men. https://www.renalandurologynews.com/delayed-use-of-radium-223-in-black-prostate-cancer-patients/article/834650/ Fri, 15 Feb 2019 18:38:27 GMT Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men. https://www.renalandurologynews.com/delayed-use-of-radium-223-in-black-prostate-cancer-patients/article/834650/ Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found. https://www.renalandurologynews.com/external-beam-radiation-therapy-continues-to-overtake-brachytherapy-for-prostate-cancer/article/834649/ Fri, 15 Feb 2019 18:24:17 GMT Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found. https://www.renalandurologynews.com/external-beam-radiation-therapy-continues-to-overtake-brachytherapy-for-prostate-cancer/article/834649/ At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%. https://www.renalandurologynews.com/prostate-cancer-pca-abiraterone-prednisone-adt-durable-efficacy/article/834456/ Fri, 15 Feb 2019 16:00:00 GMT At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%. https://www.renalandurologynews.com/prostate-cancer-pca-abiraterone-prednisone-adt-durable-efficacy/article/834456/ By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases. https://www.renalandurologynews.com/prostate-cancer-responds-novel-radiation-therapy-risk/article/834457/ Fri, 15 Feb 2019 15:30:00 GMT By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases. https://www.renalandurologynews.com/prostate-cancer-responds-novel-radiation-therapy-risk/article/834457/ After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. https://www.renalandurologynews.com/prostate-cancer-apalutamide-trial-update-treatment-risk/article/834459/ Fri, 15 Feb 2019 15:00:00 GMT After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. https://www.renalandurologynews.com/prostate-cancer-apalutamide-trial-update-treatment-risk/article/834459/ Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment. https://www.renalandurologynews.com/etelcalcetide-found-to-increase-bone-mineral-density-in-shpt/article/810686/ Sat, 27 Oct 2018 20:19:57 GMT Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment. https://www.renalandurologynews.com/etelcalcetide-found-to-increase-bone-mineral-density-in-shpt/article/810686/ Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels. https://www.renalandurologynews.com/ankle-brachial-index-predicts-vascular-calcification-in-shpt/article/810684/ Sat, 27 Oct 2018 19:05:00 GMT Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels. https://www.renalandurologynews.com/ankle-brachial-index-predicts-vascular-calcification-in-shpt/article/810684/ Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds. https://www.renalandurologynews.com/epoetin-dose-linked-with-cvd-mortality-in-hemodialysis/article/810683/ Sat, 27 Oct 2018 19:00:00 GMT Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds. https://www.renalandurologynews.com/epoetin-dose-linked-with-cvd-mortality-in-hemodialysis/article/810683/ In a study, IV iron was associated with twice the risk for infections in CKD. https://www.renalandurologynews.com/iv-iron-therapy-in-ckd-increases-infection-risk/article/810682/ Sat, 27 Oct 2018 18:00:00 GMT In a study, IV iron was associated with twice the risk for infections in CKD. https://www.renalandurologynews.com/iv-iron-therapy-in-ckd-increases-infection-risk/article/810682/ In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels. https://www.renalandurologynews.com/thrice-weekly-calcimimetic-dosing-feasible-for-shpt/article/810578/ Sat, 27 Oct 2018 17:30:00 GMT In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels. https://www.renalandurologynews.com/thrice-weekly-calcimimetic-dosing-feasible-for-shpt/article/810578/ In a study, patients with uncontrolled SHPT were switched from oral cinacalcet to intravenous etelcalcetide. https://www.renalandurologynews.com/etelcalcetide-beneficial-in-severe-shpt-uncontrolled-with-cinacalcet/article/810685/ Sat, 27 Oct 2018 17:13:00 GMT In a study, patients with uncontrolled SHPT were switched from oral cinacalcet to intravenous etelcalcetide. https://www.renalandurologynews.com/etelcalcetide-beneficial-in-severe-shpt-uncontrolled-with-cinacalcet/article/810685/ Loss of renal function may not be the sole factor in SHPT development, according to new study findings. https://www.renalandurologynews.com/predictors-of-shpt-progression-in-ckd-identified/article/810395/ Sat, 27 Oct 2018 17:05:00 GMT Loss of renal function may not be the sole factor in SHPT development, according to new study findings. https://www.renalandurologynews.com/predictors-of-shpt-progression-in-ckd-identified/article/810395/ In a study of 933 individuals with a mean age of 78 years, higher serum uromodulin was associated with a lower risk of end-stage renal disease. https://www.renalandurologynews.com/kidney-failure-in-the-elderly-linked-to-low-serum-uromodulin/article/810389/ Sat, 27 Oct 2018 15:00:00 GMT In a study of 933 individuals with a mean age of 78 years, higher serum uromodulin was associated with a lower risk of end-stage renal disease. https://www.renalandurologynews.com/kidney-failure-in-the-elderly-linked-to-low-serum-uromodulin/article/810389/ Taiwan study reveals a 38% increased risk of ischemic stroke among patients with nephrotic syndrome. https://www.renalandurologynews.com/nephrotic-syndrome-found-to-raise-ischemic-stroke-risk/article/810391/ Sat, 27 Oct 2018 11:00:00 GMT Taiwan study reveals a 38% increased risk of ischemic stroke among patients with nephrotic syndrome. https://www.renalandurologynews.com/nephrotic-syndrome-found-to-raise-ischemic-stroke-risk/article/810391/ Patients with chronic kidney disease who have hyperuricemia have a 3-fold higher risk of all-cause mortality. https://www.renalandurologynews.com/high-uric-acid-raises-death-risk-in-ckd/article/810075/ Fri, 26 Oct 2018 17:33:00 GMT Patients with chronic kidney disease who have hyperuricemia have a 3-fold higher risk of all-cause mortality. https://www.renalandurologynews.com/high-uric-acid-raises-death-risk-in-ckd/article/810075/ Use of muscle relaxants was associated with a 68%, 29%, and 30% increased risk of altered mental status, falls, and fractures, respectively. https://www.renalandurologynews.com/hemodialysis-patient-muscle-relaxant-use-tied-to-falls-fracture/article/810070/ Fri, 26 Oct 2018 17:30:00 GMT Use of muscle relaxants was associated with a 68%, 29%, and 30% increased risk of altered mental status, falls, and fractures, respectively. https://www.renalandurologynews.com/hemodialysis-patient-muscle-relaxant-use-tied-to-falls-fracture/article/810070/ Statin use vs non-use among patients hospitalized with dialysis-requiring acute kidney injury is associated with decreased risks of 1-year and in-hospital all-cause mortality, a study found. https://www.renalandurologynews.com/statins-reduce-mortality-risk-in-dialysis-requiring-aki/article/810080/ Fri, 26 Oct 2018 17:30:00 GMT Statin use vs non-use among patients hospitalized with dialysis-requiring acute kidney injury is associated with decreased risks of 1-year and in-hospital all-cause mortality, a study found. https://www.renalandurologynews.com/statins-reduce-mortality-risk-in-dialysis-requiring-aki/article/810080/ In a study, patiromer lowered serum phosphate in patients with hyperkalemia and hyperphosphatemia. https://www.renalandurologynews.com/hyperkalemia-drug-may-act-as-phosphate-binder/article/809946/ Fri, 26 Oct 2018 17:00:00 GMT In a study, patiromer lowered serum phosphate in patients with hyperkalemia and hyperphosphatemia. https://www.renalandurologynews.com/hyperkalemia-drug-may-act-as-phosphate-binder/article/809946/ Higher percentages of women than men on hemodialysis have anemia, infections, hypertension, and diabetes, study finds. https://www.renalandurologynews.com/comorbidity-burden-in-hemodialysis-population-greater-in-women/article/809942/ Fri, 26 Oct 2018 16:00:00 GMT Higher percentages of women than men on hemodialysis have anemia, infections, hypertension, and diabetes, study finds. https://www.renalandurologynews.com/comorbidity-burden-in-hemodialysis-population-greater-in-women/article/809942/ In a study, kidney transplant recipients with a BMI (in kg/m2) higher than 35 have graft and patient outcomes similar to those with a BMI of 30 to 35. https://www.renalandurologynews.com/obesity-should-not-rule-out-kidney-transplantation/article/810066/ Fri, 26 Oct 2018 14:39:00 GMT In a study, kidney transplant recipients with a BMI (in kg/m2) higher than 35 have graft and patient outcomes similar to those with a BMI of 30 to 35. https://www.renalandurologynews.com/obesity-should-not-rule-out-kidney-transplantation/article/810066/